Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) shares, rose in value on Thursday, July 10, with the stock price up by 13.79% to the previous day’s close as strong demand from buyers drove the stock to $5.28.
Actively observing the price movement in the last trading, the stock closed the session at $4.64, falling within a range of $4.19 and $5.3758. The value of beta (5-year monthly) was 0.944. Referring to stock’s 52-week performance, its high was $10.02, and the low was $1.08. On the whole, SONN has fluctuated by 331.73% over the past month.
With the market capitalization of Sonnet BioTherapeutics Holdings Inc currently standing at about $16.72 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SONN’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of SONN currently trading nearly 142.87% and 225.73% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 86.93, while the 7-day volatility ratio is showing 28.68% which for the 30-day chart, stands at 22.49%. Furthermore, Sonnet BioTherapeutics Holdings Inc (SONN)’s beta value is 0.86.
A comparison of Sonnet BioTherapeutics Holdings Inc (SONN) with its peers suggests the former has fared considerably weaker in the market. SONN showed an intraday change of 13.79% in last session, and over the past year, it grew by 261.64%%.
Data on historical trading for Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) indicates that the trading volumes over the past 10 days have averaged 17.21 and over the past 3 months, they’ve averaged 2.84 million. According to company’s latest data on outstanding shares, there are 3.17 million shares outstanding.
Nearly 1.17% of Sonnet BioTherapeutics Holdings Inc’s shares belong to company insiders and institutional investors own 5.09% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 60829.0 shares as on 2025-06-13, resulting in a short ratio of 1.57. According to the data, the short interest in Sonnet BioTherapeutics Holdings Inc (SONN) stood at 194.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 98090.0. The stock has fallen by -26.67% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SONN stock heading into the next quarter.
